Amgen

2434 articles about Amgen

• NEW DATA FROM AMGEN'S PROLIA® (DENOSUMAB) DEMONSTRATES SIGNIFICANT REDUCTION IN OSTEOPOROTIC FRACTURE RISK COMPARED TO ALENDRONATE

  5/8/2023

  Amgen (NASDAQ:AMGN) today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia® (denosumab) injection reduced fracture risk in patients versus oral alendronate, a frequently prescribed bisphosphonate treatment.

• Amgen to Present at the 2023 Bank of America Merrill Lynch Global Healthcare Conference

  5/3/2023

  Amgen will present at the 2023 Bank of America Merrill Lynch Global Healthcare Conference at 11:00 a.m. ET on Tuesday, May 9, 2023.

• 

  The Top 12 Biopharma Companies Hiring Now

  5/1/2023

  In the past few weeks, the biopharma industry has been filled with layoffs and company launches. To learn about job opportunities at some of the industry's top companies, see inside.

• Amgen Reports First Quarter 2023 Financial Results

  4/27/2023

  Amgen announced financial results for the first quarter of 2023.

• AMGEN ANNOUNCES WEBCAST OF 2023 FIRST QUARTER FINANCIAL RESULTS

  4/21/2023

  Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Thursday, April 27, 2023, after the close of the U.S. financial markets.

• 

  Lilly Seeks First-Line KRAS Treatment with AACR Data Release

  4/19/2023

  Lilly investigators said they hoped to differentiate their Phase I candidate from the competitive KRAS space by making it the first to gain approval as a first-line treatment.

• Amgen and NSG Biolabs Announce Albatroz Therapeutics as Winner of First Amgen Golden Ticket in Singapore

  3/20/2023

  Leading global biotechnology company Amgen and NSG BioLabs, Singapore's largest and leading provider of biotechnology co-working laboratories and offices, announced Albatroz Therapeutics as the winner of the first Amgen Golden Ticket in Singapore.

• 

  Amgen Cuts 450 Jobs in Second Round of Layoffs This Year

  3/17/2023

  Amgen is terminating 450 workers in hopes of weathering dropping drug prices and rising inflation. This is Amgen's second round of job cuts this year.

• Amgen to Present at the 33rd Annual Oppenheimer Healthcare Conference

  3/9/2023

  Amgen will present at the 2023 Oppenheimer Healthcare Conference at 2:00 p.m. ET on Monday, March 13, 2023.

• AMGEN ANNOUNCES 2023 SECOND QUARTER DIVIDEND

  3/7/2023

  Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.13 per share dividend for the second quarter of 2023.

• Amgen to Present at the 43rd Annual TD Cowen Healthcare Conference

  3/3/2023

  Amgen will present at the 2023 TD Cowen Healthcare Conference at 11:10 a.m. ET on Wednesday, March 8, 2023.

• AMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC

  3/1/2023

  Amgen (NASDAQ: AMGN) today announced new Repatha® (evolocumab) combined data from the Phase 3 FOURIER and FOURIER Open Label Extension (OLE) studies and the Phase 2 OCEAN(a)-DOSE study of investigational olpasiran, an siRNA that reduces lipoprotein(a) [Lp(a)] by more than 90%.

• AMGEN ANNOUNCES CARDIOVASCULAR STUDY TO EVALUATE ASSOCIATION BETWEEN LIPOPROTEIN(a) AND CARDIOVASCULAR RISK IN AFRICAN AMERICANS

  2/22/2023

  Amgen (NASDAQ:AMGN) today announced the African American Heart Study, in collaboration with the Association of Black Cardiologists (ABC) and the Morehouse School of Medicine (MSM), which will measure the association between Lipoprotein(a), or Lp(a), and atherosclerotic cardiovascular disease (ASCVD) in 5,000 African American individuals across the United States

• AMGEN TO PRESENT AT THE 2023 SVB SECURITIES GLOBAL BIOPHARMA CONFERENCE

  2/9/2023

  Amgen (NASDAQ:AMGN) will present at the 2023 SVB Securities Global Biopharma Conference at 10:40 a.m. ET on Tuesday, February 14, 2023.

• TEZSPIRE® approved for self-administration in the US with a new pre-filled pen

  2/2/2023

  AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab-ekko) has been approved in the US for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.

• TEZSPIRE® APPROVED FOR SELF-ADMINISTRATION IN THE U.S. WITH A NEW PRE-FILLED PEN

  2/2/2023

  Amgen (NASDAQ:AMGN) and AstraZeneca today announced the U.S. Food and Drug Administration (FDA) has approved TEZSPIRE® (tezepelumab-ekko) for self-administration in a pre-filled, single-use pen for patients aged 12 years and older with severe asthma.

• Amgen Posts Full Transcript and Audio Replay of Fourth Quarter and Full Year 2022 Earnings Webcast

  2/1/2023

  Amgen posted the full transcript and audio replay of the company's 2022 fourth quarter and full year financial results webcast from earlier.

• AMJEVITA™ (ADALIMUMAB-ATTO), FIRST BIOSIMILAR TO HUMIRA®, NOW AVAILABLE IN THE UNITED STATES

  1/31/2023

  Amgen (NASDAQ:AMGN) today announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira ®*  (adalimumab), is now available in the United States.

• AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS

  1/31/2023

  Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year 2022 versus comparable periods in 2021.

• 

  Amgen Downsizes by 300 Amid Industry Constriction

  1/30/2023

  Amgen is implementing organizational changes including laying off approximately 300 team members, confirmed Monday.